CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-3190
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Investigational Agents in Immunotherapy: A New Horizon for the Treatment of Multiple Myeloma

British Journal of Haematology
Hematology
2018English

CD38-driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma

Cancer Research
Cancer ResearchOncology
2019English

Lipid Raft-Targeted Therapy in Multiple Myeloma

Oncogene
Cancer ResearchGeneticsMolecular Biology
2010English

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Mechanism of Action of a New Anti-Cd38 Antibody: Enhancing Myeloma Immunotherapy

Clinical Cancer Research
Cancer ResearchOncology
2019English

The Mechanism of Action of the Anti-Cd38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2015English

Retreatment With Bendamustine-Bortezomib-Dexamethasone in a Patient With Relapsed/Refractory Multiple Myeloma

Case Reports in Hematology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy